In preparation for the upcoming winter season, predicted to bring
below-average temperatures and heavy snowstorms, Ryder
System, Inc. (NYSE:R), a leader in commercial
fleet management and supply
chain solutions , is sharing best practices to help fleets get winter
By Barbara Kollmeyer, MarketWatch
MADRID (MarketWatch) -- Wall Street was poised for a stronger start on Wednesday, with stock futures gaining after Republicans retook control of the Senate after a string of midterm election victories on Tuesday.
Nu Skin Enterprises' stock (NUS) tumbled 12% in premarket trade Wednesday, after the maker of skin care products provided a profit and sales outlook for the current quarter that was well below analyst projections.
By Michael Brush, MarketWatch
(This article was first published in October and updated on Wednesday to reflect the election result)
It's the elections, stupid!
Many investors are so focused on headline-grabbing issues like global growth and Fed interest rate policy, they're missing two key election themes telling us it's time to overweight stocks.
Targacept, Inc. (NASDAQ: TRGT ),
a clinical-stage biopharmaceutical company advancing NNR Therapeutics™,
today reported its financial results for the third quarter and nine
months ended September 30, 2014.
Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial
results for the third quarter of 2014, including revenue from sales of Iclusig ®
(ponatinib). The Company also provided an update on corporate
By Kirsten Grind
Investors yanked an industry record $27.5 billion from Pacific Investment Management Co.'s flagship fund last month as the surprise exit of co-founder Bill Gross took its toll on the firm he co-founded.
Vishay Precision Group, Inc. (NYSE: VPG), a leading producer of
precision sensors and systems, based on its resistive foil technology,
today announced financial results for its third quarter ended September
Sciences Corporation (NYSE: ORB), one of the world’s leading space
technology companies, today announced comprehensive plans to fulfill its
contract commitments under NASA’s Commercial Resupply Services (CRS)
program as well as to accelerate an upgrade of the Antares
medium-class launcher’s main propulsion system.
- Third quarter contract revenue of $57.5 million, up 8% from 2013 - Lower Discovery and API revenue is offset by addition of OsoBio - OsoBio business interruption contributes to third quarter adjusted loss per share of $(0.02)
- Full year 2014 contract revenue expected to be between $253 and $261 million, an increase of 22% at the midpoint - Full year adjusted diluted EPS range between $0.67 and $0.73, compared to $0.70 in 2013 - Company provides initial 2015 outlook - Company creates new Drug Product reporting segment to reflect addition of OsoBio ALBANY, N.Y. , Nov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.